Free Trial

Amedisys (NASDAQ:AMED) Sees Unusually-High Trading Volume - Still a Buy?

Amedisys logo with Medical background

Amedisys, Inc. (NASDAQ:AMED - Get Free Report) saw strong trading volume on Monday . 186,864 shares traded hands during trading, a decline of 43% from the previous session's volume of 328,166 shares.The stock last traded at $95.18 and had previously closed at $97.22.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. Cantor Fitzgerald reiterated a "neutral" rating and set a $101.00 price target on shares of Amedisys in a research report on Thursday, July 25th. William Blair cut shares of Amedisys from an "outperform" rating to a "market perform" rating in a research report on Monday, July 1st. Finally, Deutsche Bank Aktiengesellschaft cut shares of Amedisys from a "buy" rating to a "hold" rating and set a $101.00 price target on the stock. in a research report on Monday, July 29th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $100.67.

View Our Latest Research Report on Amedisys

Amedisys Trading Down 1.8 %

The firm has a market cap of $3.12 billion, a PE ratio of -149.20, a PEG ratio of 1.89 and a beta of 0.78. The company has a quick ratio of 1.16, a current ratio of 1.16 and a debt-to-equity ratio of 0.30. The stock's fifty day simple moving average is $97.04 and its two-hundred day simple moving average is $95.58.

Institutional Investors Weigh In On Amedisys

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Alpine Associates Management Inc. lifted its stake in shares of Amedisys by 0.9% in the second quarter. Alpine Associates Management Inc. now owns 1,280,897 shares of the health services provider's stock worth $117,586,000 after buying an additional 11,000 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Amedisys by 4.0% in the second quarter. Dimensional Fund Advisors LP now owns 514,166 shares of the health services provider's stock worth $47,202,000 after buying an additional 19,660 shares in the last quarter. Calamos Advisors LLC lifted its stake in shares of Amedisys by 11.6% in the second quarter. Calamos Advisors LLC now owns 397,347 shares of the health services provider's stock worth $36,476,000 after buying an additional 41,220 shares in the last quarter. Highbridge Capital Management LLC lifted its stake in shares of Amedisys by 34.7% in the second quarter. Highbridge Capital Management LLC now owns 323,200 shares of the health services provider's stock worth $29,670,000 after buying an additional 83,200 shares in the last quarter. Finally, SG Americas Securities LLC lifted its stake in shares of Amedisys by 413.4% in the third quarter. SG Americas Securities LLC now owns 196,713 shares of the health services provider's stock worth $18,985,000 after buying an additional 158,398 shares in the last quarter. Hedge funds and other institutional investors own 94.36% of the company's stock.

Amedisys Company Profile

(Get Free Report)

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

Recommended Stories

Should you invest $1,000 in Amedisys right now?

Before you consider Amedisys, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amedisys wasn't on the list.

While Amedisys currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Post-Election Chaos or Opportunity? Prepare Your Investments
Strong Markets Meet Rising Volatility—Are Your Investments Safe?
Analysts Bullish on AI-Powered Healthcare: Intuitive Surgical’s 30% Upside

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines